Daily Stock Analysis, ALIM, Alimera Sciences Inc, priceseries

Alimera Sciences Inc. Daily Stock Analysis
Stock Information
Open
1.46
Close
1.48
High
1.49
Low
1.43
Previous Close
1.45
Daily Price Gain
0.03
YTD High
1.72
YTD High Date
Mar 16, 2017
YTD Low
1.10
YTD Low Date
Jan 3, 2017
YTD Price Change
0.36
YTD Gain
32.14%
52 Week High
2.40
52 Week High Date
Aug 4, 2016
52 Week Low
1.01
52 Week Low Date
Jul 22, 2016
52 Week Price Change
-0.08
52 Week Gain
-5.13%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 10. 2015
4.66
Apr 22. 2015
4.93
8 Trading Days
5.78%
Link
LONG
Mar 31. 2016
1.75
Apr 29. 2016
2.25
21 Trading Days
28.53%
Link
LONG
Jul 26. 2016
1.69
Jul 27. 2016
1.78
1 Trading Days
5.33%
Link
LONG
Aug 3. 2016
2.00
Aug 4. 2016
2.20
1 Trading Days
10.00%
Link
LONG
Mar 8. 2017
1.31
Mar 20. 2017
1.49
8 Trading Days
13.93%
Link
Company Information
Stock Symbol
ALIM
Exchange
NasdaqGM
Company URL
www.alimerasciences.com
Company Phone
6789905740
CEO
Charles Daniel Myers
Headquarters
Georgia
Business Address
6120 WINDWARD PARKWAY, STE 290, ALPHARETTA, GA 30005
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001267602
About

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by Daniel C. Myers and David R. Holland and is headquartered in Alpharetta, GA.

Description

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, Portugal, and the United Kingdom. The company focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a constant micro-dose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. It has license agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.